0000000000014369

AUTHOR

Irene Aldás

showing 4 related works from this author

Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac)

2020

Community-acquired pneumonia (CAP) remains the first cause of morbidity and mortality worldwide due to infection. Several aspects such as severity and host response are related to its clinical course and outcome. Beyond the acute implications that the infection provokes in the host, pneumonia also has long-term negative consequences. Among them, cardiovascular complications and mortality are the most outstanding. Therefore, an adequate recognition and stratification of the risk of complications and mortality is crucial. Many biomarkers have been studied for these reasons, considering that each biomarker mirrors a different aspect. Moreover, the clinical application of many of them is still …

medicine.medical_specialtybusiness.industrycardiaccardiovascularlcsh:RClinical courseHost responsebiomarkerslcsh:MedicineGeneral MedicineDiseaseReviewmedicine.disease03 medical and health sciencesPneumonia0302 clinical medicine030228 respiratory systemCommunity-acquired pneumoniamedicineBiomarker (medicine)pneumonia030212 general & internal medicinebusinessIntensive care medicineJournal of Clinical Medicine
researchProduct

Eventos cardiovasculares tempranos y tardíos en pacientes ingresados por neumonía adquirida en la comunidad

2020

Resumen Introduccion La neumonia adquirida en la comunidad se asocia al desarrollo de eventos cardiovasculares (ECV). El objetivo del estudio fue analizar los factores relativos al huesped, la gravedad y la etiologia que se asocian con la aparicion de estos eventos, tempranos y tardios, y su impacto en la mortalidad. Metodo Estudio prospectivo de cohortes multicentrico en pacientes ingresados por neumonia. Se recogieron ECV durante el ingreso, a los 30 dias (tempranos) y al ano (tardios) y la mortalidad. Resultados Doscientos dos de 1.967 (10,42%) pacientes presentaron ECV tempranos y 122 (6,64%) tardios. El 16% de la mortalidad al ano se atribuyo a complicaciones cardiovasculares. Los fact…

Pulmonary and Respiratory MedicineGynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicine030228 respiratory systembusiness.industryMedicinebusinessArchivos de Bronconeumología
researchProduct

Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia

2020

Abstract Introduction Community-acquired pneumonia increases the risk of cardiovascular events (CVE). The objective of this study was to analyze host, severity, and etiology factors associated with the appearance of early and late events and their impact on mortality. Method Prospective multicenter cohort study in patients hospitalized for pneumonia. CVE and mortality rates were collected at admission, 30-day follow-up (early events), and one-year follow-up (late events). Results In total, 202 of 1967 (10.42%) patients presented early CVE and 122 (6.64%) late events; 16% of 1-year mortality was attributed to cardiovascular disease. The host risk factors related to cardiovascular complicatio…

medicine.medical_specialtybusiness.industryPneumonia severity indexMortality rateGeneral MedicineDiseasemedicine.diseasePneumoniaCommunity-acquired pneumoniaInternal medicinemedicineEtiologyRisk factorbusinessCohort studyArchivos de Bronconeumología (English Edition)
researchProduct

Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers.

2019

Background Community-acquired pneumonia (CAP) increases the risk of cardiovascular complications during and following the episode. The goal of this study was to determine the usefulness of cardiovascular and inflammatory biomarkers for assessing the risk of early (within 30 days) or long-term (1-year follow-up) cardiovascular events. Methods A total of 730 hospitalized patients with CAP were prospectively followed up during 1 year. Cardiovascular (proadrenomedullin [proADM], pro-B-type natriuretic peptide (proBNP), proendothelin-1, and troponin T) and inflammatory (interleukin 6 [IL-6], C-reactive protein, and procalcitonin) biomarkers were measured on day 1, at day 4/5, and at day 30. Resu…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyTime Factorsmedicine.drug_classCritical Care and Intensive Care MedicineRisk AssessmentProcalcitonin03 medical and health sciences0302 clinical medicineCommunity-acquired pneumoniaInternal medicineNatriuretic peptidePneumonia BacterialMedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedAged 80 and overbiologyTroponin Tbusiness.industryC-reactive proteinMiddle Agedmedicine.diseaseTroponinCommunity-Acquired InfectionsPneumonia030228 respiratory systemCardiovascular Diseasesbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersChest
researchProduct